Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
45.04
-1.48 (-3.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Apogee Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -146.66 | -83.99 | -43.4 |
| Loss (Gain) From Sale of Investments | -12.09 | -3.07 | - |
| Stock-Based Compensation | 17.93 | 6.1 | 2.34 |
| Other Operating Activities | 1.02 | 0.09 | 12.44 |
| Change in Accounts Payable | 1.11 | 1.61 | 0.46 |
| Change in Other Net Operating Assets | 5.37 | 4.49 | 10.25 |
| Operating Cash Flow | -133.21 | -74.76 | -17.92 |
| Capital Expenditures | -1.32 | -0.17 | - |
| Investment in Securities | -385.2 | -273.74 | - |
| Investing Cash Flow | -386.52 | -273.91 | - |
| Issuance of Common Stock | 450.54 | 315.39 | - |
| Other Financing Activities | - | - | -0.75 |
| Financing Cash Flow | 450.54 | 315.39 | 183.62 |
| Net Cash Flow | -69.2 | -33.28 | 165.7 |
| Free Cash Flow | -134.53 | -74.93 | -17.92 |
| Free Cash Flow Per Share | -2.54 | -3.00 | -7.28 |
| Levered Free Cash Flow | -86.91 | -45.5 | - |
| Unlevered Free Cash Flow | -86.91 | -45.5 | - |
| Change in Net Working Capital | -7.7 | -6.69 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.